Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

Inclusion Criteria: Patients: * Age\>18 years * Informed consent signed by the patient * Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis * Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \[1\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction). Healthy controls : * Age\>18 years * Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants * Informed consent signed by the patient * Absence of known cutaneous inflammatory disease. Exclusion Criteria: * Under guardianship or curatorship * Pregnant or breastfeeding woman * Lack of affiliation with a social security system * Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.